Factors affecting uptake of the levonorgestrel-releasing intrauterine device: A mixed-method study of social franchise clients in Nigeria

被引:4
|
作者
Brunie, Aurelie [1 ]
Nwala, Anthony Adindu [2 ]
Stankevitz, Kayla [3 ]
Lydon, Megan [3 ]
Danna, Kendal [4 ]
Afolabi, Kayode [5 ]
Rademacher, Kate H. [3 ]
机构
[1] FHI 360, Washington, DC USA
[2] Soc Family Hlth, Abuja, Nigeria
[3] FHI 360, Durham, NC 27701 USA
[4] Populat Serv Int, Washington, DC USA
[5] Fed Minist Hlth, Abuja, Nigeria
来源
PLOS ONE | 2021年 / 16卷 / 09期
基金
比尔及梅琳达.盖茨基金会;
关键词
IMPLANT REMOVAL SERVICES; SYSTEM; ACCESS; QUALITY; REASONS; WOMEN;
D O I
10.1371/journal.pone.0257769
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Despite the positive characteristics of the levonorgestrel-releasing intrauterine device (IUD)-a long-acting, highly effective contraceptive with important non-contraceptive attributes-the method has not been widely available in low- and middle-income countries. This study of hormonal IUD, copper IUD, implant and injectable users in Nigeria compares their characteristics, reasons for method choice, and experiences obtaining their method. Methods We conducted a phone survey with 888 women who received a hormonal IUD, copper IUD, contraceptive implant or injectable from 40 social franchise clinics across 18 states in Nigeria. We analyzed survey data descriptively by method and assessed factors associated with hormonal IUD use through multivariate logistic regression models. Follow-up in-depth interviews conducted with 32 women were analyzed thematically. Results There were few differences by method used in the socio-demographic profiles and contraceptive history of participants. Among users choosing a long-acting, reversible method, the top reasons for method choice included perceptions that the method was "right for my body," long duration, recommended by provider, recommended by friends/family, few or manageable side effects, and high effectiveness. Among hormonal IUD users, 17% mentioned reduced bleeding (inclusive of lighter, shorter, or no period), and 16% mentioned treatment of heavy or painful periods. Qualitative data supported these findings. Among survey respondents, between 25% and 33% said they would have chosen no method if the method they received had not been available. Both quantitative and qualitative data indicated that partner support can affect contraceptive use, with in-depth interviews revealing that women typically needed partner permission to use contraception, but men were less influential in method choice. Conclusions Expanding access to the hormonal IUD as part of a full method mix provides an opportunity to expand contraceptive choice for women in Nigeria. Findings are timely as the government is poised to introduce the method on a wider scale.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system
    Youm, Jina
    Lee, Hyun Ju
    Kim, Seul Ki
    Kim, Hoon
    Jee, Byung Chul
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2014, 126 (02) : 165 - 169
  • [2] The levonorgestrel-releasing intrauterine device is related to early emotional reactivity: An ERP study
    Zelionkait, Ingrida
    Gaizauskaite, Rimante
    Uusberg, Helen
    Uusberg, Andero
    Ambrase, Aiste
    Derntl, Birgit
    Griksiene, Ramune
    PSYCHONEUROENDOCRINOLOGY, 2024, 162
  • [3] Efficacy of the levonorgestrel-releasing intrauterine device is associated with different subtypes of adenomyosis: a retrospective study
    Chen, Shuyi
    Wang, Jianzhang
    Sun, Wenting
    Zhu, Libo
    He, Jiayi
    Zhang, Xinmei
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (21)
  • [4] Efficacy of hysteroscopic levonorgestrel-releasing intrauterine device fixation in the treatment of adenomyosis: A cohort study
    Xu, Pan
    Ling, Shanshan
    Hu, E.
    Ma, Lina
    Liu, Jie
    Yi, Bixia
    BIOMEDICAL REPORTS, 2024, 21 (01)
  • [5] Case-control study of breast cancer risk for a levonorgestrel-releasing intrauterine device
    Dinger, Juergen
    Moehner, Sabine
    Assmann, Anita
    Thai, Do Minh
    Heinemann, Lothar
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S259 - S260
  • [6] Effect of levonorgestrel-releasing intrauterine device on menorrhagia and dysmenorrhoea and uterine volume in adenomyosis: a pilot study
    Choudhary, D.
    Vaid, N.
    Guleria, K.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 : 48 - 48
  • [7] Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden
    Yi, Huan
    Zhang, Naiqi
    Huang, Jimiao
    Zheng, Ying
    Hong, Qiu hua
    Sundquist, Jan
    Sundquist, Kristina
    Zheng, Xiangqin
    Ji, Jianguang
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 231 (04) : 450e1 - 450e12
  • [8] Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena)
    Zhou, LF
    Harrison-Woolrych, M
    Coulter, DM
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (05) : 371 - 377
  • [9] EFFECTIVE CONTRACEPTION WITH THE LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE - 12-MONTH REPORT OF A EUROPEAN MULTICENTER STUDY
    LUUKKAINEN, T
    ALLONEN, H
    HAUKKAMAA, M
    HOLMA, P
    PYORALA, T
    TERHO, J
    TOIVONEN, J
    BATAR, I
    LAMPE, L
    ANDERSSON, K
    ATTERFELDT, P
    JOHANSSON, DB
    NILSSON, S
    NYGREN, KG
    ODLIND, V
    OLSSON, SE
    RYBO, G
    SIKSTROM, B
    NIELSEN, NC
    BUCH, A
    OSLER, M
    STEIER, A
    ULSTEIN, M
    CONTRACEPTION, 1987, 36 (02) : 169 - 179
  • [10] 2 YEARS EXPERIENCE WITH 2 LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICES AND ONE COPPER-RELEASING INTRAUTERINE-DEVICE - A RANDOMIZED COMPARATIVE PERFORMANCE STUDY
    NILSSON, CG
    ALLONEN, H
    DIAZ, J
    LUUKKAINEN, T
    FERTILITY AND STERILITY, 1983, 39 (02) : 187 - 192